{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bimekizumab", "query": { "intervention": "Bimekizumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 43, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bimekizumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T06:06:17.535Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06921850", "title": "A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "9 Years to 17 Years" }, "enrollment_count": 43, "start_date": "2025-04-07", "completion_date": "2029-03-06", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Roseville, California • Sacramento, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06921850" }, { "nct_id": "NCT04242498", "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 509, "start_date": "2020-03-02", "completion_date": "2022-09-28", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 24, "location_summary": "Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orange Park", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04242498" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-12-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT03895385", "title": "A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 56, "start_date": "2019-04-02", "completion_date": "2019-10-04", "has_results": false, "last_update_posted_date": "2020-09-17", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03895385" }, { "nct_id": "NCT03248531", "title": "A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2017-09-22", "completion_date": "2019-02-21", "has_results": true, "last_update_posted_date": "2022-04-11", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 11, "location_summary": "Los Angeles, California • Coral Gables, Florida • Orange, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Orange", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03248531" }, { "nct_id": "NCT03230292", "title": "A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 43, "start_date": "2017-07-03", "completion_date": "2019-03-06", "has_results": true, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 2, "location_summary": "High Point, North Carolina • Bexley, Ohio", "locations": [ { "city": "High Point", "state": "North Carolina" }, { "city": "Bexley", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03230292" }, { "nct_id": "NCT06336343", "title": "Bimekizumab in Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-06-03", "completion_date": "2026-03-17", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 2, "location_summary": "East Windsor, New Jersey • New York, New York", "locations": [ { "city": "East Windsor", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06336343" }, { "nct_id": "NCT06624228", "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 553, "start_date": "2024-10-21", "completion_date": "2026-06-03", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 34, "location_summary": "Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 31 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06624228" }, { "nct_id": "NCT03370133", "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis", "Moderate to Severe Chronic Plaque Psoriasis", "Psoriatic Arthritis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2017-12-06", "completion_date": "2019-12-13", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Boynton Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03370133" }, { "nct_id": "NCT02905006", "title": "Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2016-08", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2022-07-21", "last_synced_at": "2026-09-03T06:06:17.535Z", "location_count": 11, "location_summary": "Fremont, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "West Des Moines", "state": "Iowa" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02905006" } ] }